Efficacy of Xenograft Alone or Mixed With Arginyl-Glycyl-Aspartic Acid (RGD) in Horizontal Ridge Augmentation With Split-crest Technique for Implant Placement

NCT ID: NCT06585852

Last Updated: 2024-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-01

Study Completion Date

2024-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the present study is to evaluate the efficacy of xenograft alone or xenograft mixed with Arginylglycylaspartic acid (RGD) , in horizontal ridge augmentation with split-crest technique, for implant placement.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A comparative study for ridge augmentation procedure, With two groups. First group underwent a surgical ridge splitting procedure with ultrasonic bone surgery and grafting with Xenograft alone and implant placement. Second group underwent a surgical ridge splitting procedure with ultrasonic bone surgery Xenograft mix ed with Arginylglycylaspartic acid (RGD) and implant placement.

Both groups were followed up for 1 and 3 months after loading.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Implant Dentistry

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

Xenograft alone with split-crest technique by ultrasonic bone surgery and implant placement.

Group Type ACTIVE_COMPARATOR

Xenograft

Intervention Type DRUG

Scaffold material of choice

Split crest technique

Intervention Type PROCEDURE

Piezoelectric surgery

Study Group

Xenograft mixed with RGD with split-crest technique by ultrasonic bone surgery and implant placement.

Group Type EXPERIMENTAL

RGD

Intervention Type DRUG

Study group main material

Xenograft

Intervention Type DRUG

Scaffold material of choice

Split crest technique

Intervention Type PROCEDURE

Piezoelectric surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RGD

Study group main material

Intervention Type DRUG

Xenograft

Scaffold material of choice

Intervention Type DRUG

Split crest technique

Piezoelectric surgery

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Arginylglycylaspartic acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults (age 18-30) exhibiting initial insufficiently bone width.
2. Patients with good oral hygiene.
3. Patients must be free from systemic diseases that may influence the outcome of the therapy.
4. Patients with bony horizontal defects alone, Class III \& IV.

Exclusion Criteria

1. Heavy smokers.
2. Patient treated by immunosuppressive chemotherapy or radio therapy,
3. Allergy to any material or medication used in the study.
4. Pregnant females.
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Al-Azhar University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

muhammed nagy

Principle investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Al Azhar University of Cairo

Cairo, Nasr City, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mahmoud Taha, PHD

Role: CONTACT

01225864104

Ibrahim Sabri

Role: CONTACT

01007809113

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mahmoud El Destawy, PHD

Role: primary

+201225864104

Ibrahim Sabri, PHD

Role: backup

+20 100 780 9113

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RGD in Ridge splitting

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.